Calidi Biotherapeutics

Calidi Biotherapeutics Gross Margin

The Gross Margin of Calidi Biotherapeutics (CLDI) as of Nov 22, 2026 is -508.89 %. In the previous year, Gross Margin was 79.06 % — a change of -743.64% (lower).

Gross Margin

-508.89 %

YoY

-743.64%

Last updated:

Gross Margin of Calidi Biotherapeutics is 2022 -508.89 % . Gross Margin of Calidi Biotherapeutics was 2021 79.06 % . It decreases by -743.64% lower compared to the previous year.

Calidi Biotherapeutics's gross margin stands at -508.9%, down from 79.1% several years earlier.

The Calidi Biotherapeutics Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2021
79.06 USD
Jan 1, 2022
-508.89 USD
The Calidi Biotherapeutics Gross Margin history
YEARGross MarginYoY
-508.89 %-743.64%
79.06 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Calidi Biotherapeutics Stock analysis

What does Calidi Biotherapeutics do? Calidi Biotherapeutics Inc is a blank check company formed to effect a merger or business combination with one or more entities. The company focuses on advancing allogeneic stem cell platforms for delivering anti-tumor payloads and oncolytic viruses. Its products include CLD-101 (NeuroNova) for high-grade gliomas and CLD-201 (SuperNova) for solid tumors. The company targets oncology indications, aiming to treat or prevent metastatic disease through its dual approach of cell-based delivery and viral potentiation. Investors and healthcare entities interested in innovative cancer therapies are the primary buyers of its development-stage assets. The firm's business model revolves around developing and commercializing its stem cell-based delivery platforms. CLD-101 and CLD-201 are designed to protect and amplify oncolytic viruses for targeted cancer treatment. The company's focus on multiple oncology indications, such as high-grade gliomas and solid tumors, positions it to address unmet medical needs. Its dual approach of combining stem cell delivery with viral therapy offers a potential solution for metastatic disease prevention and treatment. Calidi Biotherapeutics Inc's revenue streams are derived from partnerships and licensing agreements for its platform technologies. The company's development-stage assets are targeted at oncology markets, where it collaborates with healthcare providers and research institutions. Its products are designed to enhance the efficacy of immunotherapies, making them attractive to entities seeking advanced cancer treatment solutions. The company's focus on allogeneic stem cell platforms differentiates it in the oncology sector. Calidi Biotherapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Calidi Biotherapeutics stock

Gross Margin of Calidi Biotherapeutics is -508.89 % in 2022.

Gross Margin of Calidi Biotherapeutics changed from 79.06 % to -508.89 %, representing a -743.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Calidi Biotherapeutics since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Calidi Biotherapeutics with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Calidi Biotherapeutics

All Key Metrics — Calidi Biotherapeutics